RxDoctor Payments Data

Mohan Deochand, MD

Neurology · South Miami, FLNPI 1518976729

Payments from drug & device makers

$14,150in general payments, 2019–2025

Across 845 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Jazz Pharmaceuticals Inc.$902
  • Biogen$612
  • Supernus Pharmaceuticals, Inc.$591
  • Harmony Biosciences LLC$577
  • Mallinckrodt Hospital Products Inc.$552
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$721%
  • Food & beverage$11,14596%
  • Education$3883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$3,283
Jazz Pharmaceuticals Inc.57$902
Biogen47$612
Supernus Pharmaceuticals, Inc.120$591
Harmony Biosciences LLC27$577
Mallinckrodt Hospital Products Inc.29$552
AbbVie41$535
Adamas Pharmaceuticals, Inc.40$532
Neurelis, Inc.28$507
Pfizer34$471
Lilly USA, LLC23$404
AstraZeneca(2 entities)22$365
Amgen26$335
Eisai Inc.20$331
Lundbeck LLC17$321
Teva Pharmaceuticals USA, Inc.15$300
SK Life Science, Inc.17$281
ANI Pharmaceuticals, Inc.18$252
Greenwich Biosciences, Inc.10$243
Otsuka America Pharmaceutical, Inc.12$230
TG Therapeutics, Inc.10$215
Avanir Pharmaceuticals, Inc.20$201
UCB, Inc.10$199
Takeda Pharmaceuticals U.S.A., Inc.9$188
Biohaven Pharmaceutical Holding Company Ltd.21$187
Amneal Pharmaceuticals LLC10$164
Biohaven Pharmaceuticals, Inc.17$128
Axsome Therapeutics, Inc.7$118
Acorda Therapeutics, Inc8$100
Kedrion Biopharma, Inc.5$91
Avadel CNS Pharmaceuticals, LLC4$74
Avion Pharmaceuticals5$69
Merck4$64
Abbott1$61
Corium, LLC4$52
Johnson & Johnson4$52
Idorsia Pharmaceuticals US Inc3$42
MDD US Operations, LLC3$40
EMD Serono, Inc.2$40
Aprecia Pharmaceuticals, LLC2$37
Upsher-smith Laboratories LLC3$37
Livanova USA, Inc.2$35
Kyowa Kirin, Inc.2$33
Sumitomo Pharma America, Inc.2$32
Mallinckrodt Enterprises LLC2$30
Aucta Pharmaceuticals, Inc.2$30
Impel Pharmaceuticals Inc.2$29
Sanofi2$28
Terumo Medical Corporation1$18
Bausch Health US, LLC1$17
Inspire Medical Systems, Inc.1$16
Alnylam Pharmaceuticals Inc.1$16
Genentech USA, Inc.1$15
Protega Pharmaceutials Inc1$15
CSL Behring1$15
Grifols USA, LLC1$13
Angiodynamics, Inc.1$13
Tanabe Pharma America, Inc.1$13

How this compares

$14,150 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$101,035
Medicare patients
382
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4621$420,321
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$191,663
TecfideraDimethyl Fumarate12$113,371
VumerityDiroximel Fumarate12$101,862
EpidiolexCannabidiol (Cbd)13$60,754
FycompaPerampanel28$35,846
Aimovig AutoinjectorErenumab-Aooe43$34,474
Nurtec OdtRimegepant Sulfate28$32,451
VimpatLacosamide17$23,941
UbrelvyUbrogepant18$23,049
Lacosamide103$16,149
Emgality PenGalcanezumab-Gnlm19$14,710
Dimethyl Fumarate14$12,374
Levetiracetam338$10,871
Pregabalin118$8,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kedrion Biopharma, Inc.Gammaked$91$420,32121 claims
BiogenTecfidera, Vumerity$612$215,23424 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$188$191,66315 claims
Eisai Inc.Fycompa$331$35,84628 claims
PfizerNurtec Odt, Dilantin$471$35,70754 claims
UCB, Inc.Vimpat$199$23,94117 claims
AbbVieUbrelvy$535$23,04918 claims
Upsher-smith Laboratories LLCTopiramate$37$1,852228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →